national conference presentation

• 6.

  national conference presentation

public lecture

invited lecture

• 6.

  invited lecture

research paper

• 59. A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model.

  Takahashi R #, Yamamoto K #, Toya H, Shoji H, Kawanishi K, Momosaki K, Yabe M, Takashima K, Muromoto R, Ichikawa S, Matsuda T *, Kitai Y *. Oncogene 44, 4846–4854 (2025).
  # Contributed equally. * Corresponding author.

  DOI : 10.1038/s41388-025-03641-4

  research paper

• 58.

  Echigo H, Munekane M, Fuchigami T, Washiyama K, Nakamura T, Furukawa A, Chen Z, Mishiro K, Wakabayasi H, Takahashi K, Kinuya S, Ogawa K. Eur J Nucl Med Mol Imaging (in press).

  DOI : 10.1007/s00259-025-07498-3

  research paper

• 57. Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING.

  Endo R, Ueda T, Nagaoki T, Sato Y, Maishi N, Hida K, Harashima H*, Nakamura T*.
  Biomaterials 321: 123297 (2025).

  DOI : 10.1016/j.biomaterials.2025.123297.

  research paper

• 56. Targeting tumor endothelial cells by EGCG using specific liposome delivery system inhibits vascular inflammation and thrombosis.

  Jia Z, Maishi N, Takekawa H, Matsuda A, Nakade T, Nakamura T, Harashima H, Hida Y, Hida K*.
  Cancer Medicine 13: e70462 (2024).

  DOI : 10.1002/cam4.70462

  research paper

• 55. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.

  Endo R, Ueda T, Nagaoki T, Shima N, Sato Y, Harashima H*, Nakamura T*.
  J Control Release 372: 609-618 (2024).

  DOI : 10.1016/j.jconrel.2024.06.064

  research paper